Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression inERG-fusion-positive cancers

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

(2012) Antje Krohn et al.   AMERICAN JOURNAL OF PATHOLOGY

Phase II trial of temsirolimus in patients with metastatic breast cancer

(2012) Gini F. Fleming et al.   BREAST CANCER RESEARCH AND TREATMENT

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

(2012) C. Renner et al.   HAEMATOLOGICA

ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

(2011) Sarah Minner et al.   CLINICAL CANCER RESEARCH

Full Functional-Length Urethral Sphincter Preservation During Radical Prostatectomy

(2011) Thorsten Schlomm et al.   EUROPEAN UROLOGY

Current and future directions in mammalian target of rapamycin inhibitors development

(2011) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

New phosphatidylinositol 3-kinase inhibitors for cancer

(2011) Daniel W Bowles et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Common Gene Rearrangements in Prostate Cancer

(2011) Mark A. Rubin et al.   JOURNAL OF CLINICAL ONCOLOGY

The genomic complexity of primary human prostate cancer

(2011) Michael F. Berger et al.   NATURE

Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review

(2011) C. B. Boers-Doets et al.   ONCOLOGIST

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

(2010) S. Minner et al.   CLINICAL CANCER RESEARCH

Immunohistochemical examination of the mTORC1 pathway in high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinomas (PCa): A tissue microarray study (TMA)

(2010) Sevan Evren et al.   PROSTATE

High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer

(2010) Sarah Minner et al.   PROSTATE

Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics

(2009) Bo Dai et al.   BJU INTERNATIONAL

TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2

(2009) J. Copp et al.   CANCER RESEARCH

Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer

(2009) Chunru Lin et al.   CELL

PTENgenomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer

(2009) Kanishka Sircar et al.   JOURNAL OF PATHOLOGY

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

(2009) Bo Han et al.   MODERN PATHOLOGY

Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer

(2009) R.-S. Mani et al.   SCIENCE

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival

(2008) Y Wang et al.   ONCOGENE

Aktive Überwachung des Prostatakarzinoms

(2008) M. Graefen et al.   UROLOGE